Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to -$0.42.

  • Enanta Pharmaceuticals' EPS (Basic) rose 6000.0% to -$0.42 in Q4 2025 from the same period last year, while for Dec 2025 it was -$3.21, marking a year-over-year increase of 3515.15%. This contributed to the annual value of -$3832.8 for FY2025, which is 6984193.02% down from last year.
  • According to the latest figures from Q4 2025, Enanta Pharmaceuticals' EPS (Basic) is -$0.42, which was up 6000.0% from -$871.2 recorded in Q3 2025.
  • In the past 5 years, Enanta Pharmaceuticals' EPS (Basic) ranged from a high of -$0.42 in Q4 2025 and a low of -$871.2 during Q3 2025
  • In the last 5 years, Enanta Pharmaceuticals' EPS (Basic) had a median value of -$1.35 in 2023 and averaged -$44.79.
  • Its EPS (Basic) has fluctuated over the past 5 years, first surged by 9991.71% in 2021, then tumbled by 6395908.82% in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' EPS (Basic) (Quarter) stood at -$1.48 in 2021, then rose by 6.08% to -$1.39 in 2022, then dropped by 13.67% to -$1.58 in 2023, then skyrocketed by 33.54% to -$1.05 in 2024, then soared by 60.0% to -$0.42 in 2025.
  • Its last three reported values are -$0.42 in Q4 2025, -$871.2 for Q3 2025, and -$0.85 during Q2 2025.